Lexicon Pharmaceuticals, Inc.
8800 Technology Forest Place
The Woodlands
Texas
77381-1160
United States
Tel: 281-863-3000
Fax: 281-863-8088
Website: http://www.lexpharma.com/
415 articles about Lexicon Pharmaceuticals, Inc.
-
Lexicon Pharmaceuticals Highlights Publications Relating to Sotagliflozin's Differentiated Dual SGLT1 and SGLT2 Mechanism of Action and Potential Implications for Cardiovascular Disease
8/22/2022
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a series of publications concluding that sotagliflozin’s differentiated dual SGLT1 and SGLT2 mechanism of action may have implications for cardiovascular disease.
-
Lexicon Announces Full Exercise and Closing of Options to Purchase Additional Shares in Connection with Previously Announced Public Offering and Concurrent Private Placement
8/5/2022
Lexicon Pharmaceuticals, Inc. announced the issuance and sale of an additional 2,526,540 shares of its common stock, par value $0.001, pursuant to the full exercise of the underwriters’ option to purchase additional shares in connection with Lexicon’s previously announced public offering of Common Stock.
-
Lexicon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
8/2/2022
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended June 30, 2022 and provided an update on key milestones.
-
Lexicon Pharmaceuticals to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 2, 2022
7/29/2022
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its second quarter 2022 financial results on Tuesday, August 2, 2022 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET / 4:00 p.m. CT that day to discuss its financial and operating results and to provide a general business update.
-
Lexicon Announces Pricing of $85.0 Million Public Offering and Concurrent Private Placement
7/28/2022
Lexicon Pharmaceuticals, Inc. announced the pricing of its previously announced underwritten public offering of 16,843,600 shares of its common stock, par value $0.001.
-
Lexicon Announces Proposed Public Offering Of Common Stock - July 27, 2022
7/27/2022
Lexicon Pharmaceuticals, Inc. announced that it has commenced an underwritten public offering to offer and sell, subject to market and other conditions, shares of its common stock, par value $0.001.
-
Lexicon Announces FDA Acceptance of New Drug Application for Sotagliflozin to Treat Heart Failure
7/27/2022
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review and filed its New Drug Application (NDA) for sotagliflozin.
-
Capping off the first half of the year is a flurry of clinical trial wins. BioSpace takes a look at some of the most exciting ones:
-
Lexicon Announces Positive Top-Line Results From Phase 2 Proof-Of-Concept Study Of LX9211 In Painful Diabetic Neuropathy
6/29/2022
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced top-line results of RELIEF-DPN-1, its Phase 2 proof-of-concept study of LX9211 in painful diabetic neuropathy.
-
Lexicon Pharmaceuticals to Participate in the Jefferies 2022 Healthcare Conference
6/1/2022
Lexicon Pharmaceuticals, Inc. announced that Lonnel Coats, Lexicon’s chief executive officer, will present at the Jefferies 2022 Healthcare Conference on Wednesday, June 8, 2022 at 10:00 a.m. ET.
-
Lexicon Resubmits New Drug Application for Sotagliflozin for the Treatment of Heart Failure
5/31/2022
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has resubmitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the marketing and sale of sotagliflozin for the treatment of heart failure.
-
Lexicon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical Update
5/5/2022
Lexicon Pharmaceuticals, Inc., reported financial results for the three months ended March 31, 2022 and provided an update on key milestones.
-
Lexicon Pharmaceuticals to Host First Quarter 2022 Financial Results Conference Call and Webcast on May 5, 2022
4/29/2022
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its first quarter 2022 financial results on Thursday, May 5, 2022 before the markets open.
-
Lexicon Pharmaceuticals to Participate in the 21st Annual Needham Virtual Healthcare Conference
4/7/2022
Lexicon Pharmaceuticals, Inc. announced that Jeffrey L. Wade, Lexicon’s president and chief financial officer, will present at the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022 at 8:45 a.m. ET.
-
The 71st annual American College of Cardiology's Scientific Session saw several wins over the weekend, led by some of the life sciences industries' largest companies.
-
Lexicon Welcomes New Guidelines for the Management of Heart Failure
4/4/2022
Lexicon Pharmaceuticals, Inc. welcomes new guidelines for the management of heart failure issued jointly this past weekend by the American Heart Association, the American College of Cardiology and the Heart Failure Society of America.
-
Sotagliflozin Improved Outcomes in Patients With and Without Prior Cardiovascular Disease in New Analysis Presented at the American College of Cardiology's 71st Annual Scientific Session (ACC.22)
4/2/2022
Lexicon Pharmaceuticals, Inc. announced results of a new analysis of data from the SCORED Phase 3 clinical trial of sotagliflozin that was presented at the American College of Cardiology’s 71st Annual Scientific Session.
-
New Analysis of Cardiovascular Endpoints in the SCORED Trial to Be Presented at the American College of Cardiology’s 71st Annual Scientific Session (ACC.22)
3/21/2022
Lexicon Pharmaceuticals, Inc. announced that an analysis of sotagliflozin data from the SCORED Phase 3 clinical trial will be presented as a late-breaker at the American College of Cardiology’s 71st Annual Scientific Session.
-
Lexicon Enters Into Loan Facility With Oxford Finance for Up to $150 Million to Support Planned Commercialization of Sotagliflozin
3/17/2022
Lexicon Pharmaceuticals, Inc. announced it entered into a loan facility with Oxford Finance LLC that provides up to $150 million in borrowing capacity designed primarily to support commercial preparations and the potential launch of sotagliflozin in heart failure.
-
Lexicon Voluntarily Withdraws Sotagliflozin New Drug Application and Plans Prompt Resubmission Targeted Early Q2 2022
2/28/2022
Lexicon Pharmaceuticals, Inc. announced the voluntary withdrawal and planned near-term resubmission of the company’s New Drug Application for sotagliflozin to correct a technical issue with the submission recently identified by the company.